ストックスクリーナーアプリを入手
174.04
0.03%
-0.05
アフターアワーズ：
174.04
前日終値:
$174.09
開ける：
$174.18
24時間の取引高:
1.78M
Relative Volume:
0.63
時価総額：
$37.12B
収益：
$447.02M
当期純損益:
$-1.18B
株価収益率:
-28.16
EPS:
-6.1812
ネットキャッシュフロー:
$-906.14M
1週間 パフォーマンス:
-1.91%
1か月 パフォーマンス:
-16.23%
6か月 パフォーマンス:
+72.93%
1年 パフォーマンス:
+152.09%
1日の値動き範囲:
$173.24
$175.25
1週間の範囲:
$173.24
$179.44
52週間の値動き範囲:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
INSM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-19 | 再開されました | Truist | Buy |
| 2025-12-04 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-20 | 開始されました | William Blair | Outperform |
| 2025-08-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 開始されました | Jefferies | Buy |
| 2025-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-23 | 開始されました | Truist | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-07-26 | 開始されました | Guggenheim | Buy |
| 2022-12-09 | 開始されました | Mizuho | Buy |
| 2022-12-07 | 開始されました | Barclays | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Buy |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2021-12-06 | 開始されました | JP Morgan | Overweight |
| 2021-10-19 | 再開されました | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-10-12 | 再開されました | Stifel | Buy |
| 2019-09-03 | 開始されました | Goldman | Buy |
| 2019-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-15 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2019-01-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-08-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 開始されました | Goldman | Neutral |
| 2018-04-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 開始されました | Morgan Stanley | Overweight |
| 2018-01-18 | 開始されました | Credit Suisse | Neutral |
| 2017-09-05 | 繰り返されました | Evercore ISI | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Robert W. Baird | Outperform |
| 2016-03-15 | 開始されました | Stifel | Buy |
| 2015-11-09 | ダウングレード | UBS | Buy → Neutral |
| 2015-10-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-09 | 開始されました | Citigroup | Neutral |
| 2014-03-26 | 繰り返されました | HC Wainwright | Buy |
すべてを表示
Insmed Inc (INSM) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - FinancialContent
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Insmed's chief medical officer sells $2.97 million in stock - MSN
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INSM Quantitative Stock Analysis - Nasdaq
Rice Hall James & Associates LLC Sells 7,103 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
A Closer Look at Insmed's Options Market DynamicsInsmed (NASDAQ:INSM) - Benzinga
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Investors to Inquire about Securities Investigation - ACCESS Newswire
Insmed (FRA:IM8N) EV-to-OCF : -39.13 (As of Dec. 25, 2025) - GuruFocus
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Investors to Reach Out - ACCESS Newswire
Insmed sinks after brensocatib fails trial for sinus condition - MSN
Insmed Earnings Notes - Trefis
Insmed price target lowered to $230 from $240 at HC Wainwright - MSN
Insmed stock plunges nearly 20% after hours as sinus drug fails mid-stage trial and shows no benefit - MSN
Pharmaceutical Stocks To ConsiderDecember 21st - MarketBeat
Why Insmed Incorporated stock is considered a top pickMarket Sentiment Extremes & Free Professional Investment Consultations - Bollywood Helpline
Medical Stocks Worth WatchingDecember 18th - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Stockholders to Reach Out - ACCESS Newswire
Insmed, Inc. (NASDAQ:INSM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open - ts2.tech
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025) - ts2.tech
Insmed Incorporated(NasdaqGS: INSM) added to NASDAQ-100 Index - marketscreener.com
How analysts rate Insmed Incorporated stock today2025 Support & Resistance & Momentum Based Trading Ideas - Улправда
What is HC Wainwright's Forecast for Insmed FY2025 Earnings? - MarketBeat
Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025 - ts2.tech
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025) - ts2.tech
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN) - Benzinga
INSM stock plummets on sinus study failure, adds new pipeline asset - MSN
Voya Investment Management LLC Sells 187,840 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (BIT:1INSM) Price Target Increased by 16.99% to 218.23 - Nasdaq
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets - ts2.tech
Insmed Inc. buy Truist Financial Co. - sharewise.com
Truist Financial Upgrades Insmed (NASDAQ:INSM) to "Strong-Buy" - MarketBeat
Assenagon Asset Management S.A. Grows Position in Insmed, Inc. $INSM - MarketBeat
Will Insmed Incorporated (IM8N) stock announce a stock splitPortfolio Performance Summary & Accurate Intraday Trading Signals - ulpravda.ru
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
What risks investors should watch in Insmed Incorporated stockWeekly Risk Summary & Stock Portfolio Risk Control - ulpravda.ru
Brinsupri setback slices Insmed market cap — Clinical Report - biocentury.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
Insmed Insider Sold Shares Worth $1,786,457, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 10,699 Shares - TradingView — Track All Markets
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next - ts2.tech
Insmed (MIL:1INSM) EV-to-FCF : -35.92 (As of Dec. 19, 2025) - GuruFocus
Insmed (MIL:1INSM) EV-to-OCF : -36.87 (As of Dec. 19, 2025) - GuruFocus
Insmed Inc (INSM) 財務データ
収益
当期純利益
現金流量
EPS
0.30%
0.36%
大文字化:
|
ボリューム (24 時間):